Xenon Pharmaceuticals Inc. (XENE)
- Previous Close
40.54 - Open
41.05 - Bid 41.35 x 200
- Ask 41.86 x 300
- Day's Range
41.05 - 41.67 - 52 Week Range
27.99 - 50.99 - Volume
5,186 - Avg. Volume
348,790 - Market Cap (intraday)
3.14B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-2.73 - Earnings Date Aug 7, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
57.90
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
www.xenon-pharma.comRecent News: XENE
Performance Overview: XENE
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: XENE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: XENE
Valuation Measures
Market Cap
3.06B
Enterprise Value
2.43B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.30
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-17.09%
Return on Equity (ttm)
-23.95%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-188.6M
Diluted EPS (ttm)
-2.73
Balance Sheet and Cash Flow
Total Cash (mrq)
699.6M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--
Research Analysis: XENE
Company Insights: XENE
XENE does not have Company Insights